Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue European Urology Année : 2009

Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma.

Résumé

We present a case of previously unresectable lymphadenopathy in a patient with renal cell carcinoma treated with sunitinib. Complete resection of a 15-cm left renal cell carcinoma was initially impossible due to massive retroperitoneal disease and encasement of the great vessels and mesenteric vessels. Residual retroperitoneal disease from a radical nephrectomy was treated with the oral, multitargeted receptor tyrosine kinase inhibitor, sunitinib. Tumour shrinkage following five cycles of treatment allowed uncomplicated complete resection of the lymphadenopathy. Follow-up after 6 mo showed no evidence of disease recurrence.

Dates et versions

inserm-00325659 , version 1 (29-09-2008)

Identifiants

Citer

Jean-Jacques Patard, Rodolphe Thuret, Avakian Raffi, Brigitte Laguerre, Karim Bensalah, et al.. Treatment with Sunitinib Enabled Complete Resection of Massive Lymphadenopathy not Previously Amenable to Excision in a Patient with Renal Cell Carcinoma.. European Urology, 2009, 55 (1), pp.237-239. ⟨10.1016/j.eururo.2008.09.006⟩. ⟨inserm-00325659⟩
79 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More